PlanetMedicines

cross-posted from: https://lemmy.world/post/11525791

Dialysis centers and ketamine clinics have both met their fair share of concerns over their safety practices and high costs. But in addition to the risk of abuse, physical infrastructure and staffing require a lot of capital. Those companies developing safer, at-home psychedelic treatments could be a way to reduce costs while also reaching a larger population.>

Dialysis centers and ketamine clinics have both met their fair share of concerns over their safety practices and high costs. But in addition to the risk of abuse, physical infrastructure and staffing require a lot of capital. Those companies developing safer, at-home psychedelic treatments could be a way to reduce costs while also reaching a larger population.>

Results: Sample patients (n = 215) had a mean baseline PHQ-9 score of 18.6 and a mean of 2.1 antidepressant medication trials in the past year and 6.1 antidepressant trials in the 20 years prior to their first ketamine infusion. Frequency of infusions decreased from every 5 days to every 3–4 weeks over the first 5 months of infusions, with a mean of 18 total infusions over 12 months. After 6 weeks of treatment, 26% had a 50% improvement in PHQ-9 score (response) and 15% had PHQ-9 score ≤ 5 (remission). These improvements were similar at 12 and 26 weeks. No demographic characteristics or comorbid diagnoses were associated with 6-week PHQ-9 scores.